LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
Igenica Inc.
Headquarters:
Burlingame, CA, United States
Website:
http://www.igenica.com
Year Founded:
2009
Status:
Private
BioCentury
|
Aug 10, 2022
Management Tracks
New CMOs at Arcus, Enanta
Plus Lamba becomes CFO at ImmPACT, and updates from Appia Bio and Quanterix
Read More
BioCentury
|
Jun 17, 2016
Company News
Management tracks
Read More
BioCentury
|
Dec 14, 2015
Company News
Igenica, AstraZeneca deal
Read More
BioCentury
|
Sep 4, 2015
Company News
Management tracks
Read More
BioCentury
|
Mar 9, 2015
Finance
Column's creations
How The Column Group's long-term strategy yielded three wins
Read More
BioCentury
|
Jun 16, 2014
Emerging Company Profile
NBE: Enzymatic ADCs
NBE's enzymatic ADCs carry multiple payloads, no mutagenesis required
Read More
BioCentury
|
Apr 15, 2014
Financial News
The Column Group targeting $250 million for second fund
Read More
BioCentury
|
Mar 24, 2014
Clinical News
IGN523: Phase I started
Read More
BioCentury
|
Feb 3, 2014
Finance
Appreciating in private
Why cancer antibody play Igenica stayed with private financing
Read More
BioCentury
|
Feb 3, 2014
Financial News
Igenica financial update
Read More
Items per page:
10
1 - 10 of 19